|
|
News Breaks | | | | March 20, 2013 | | 05:30 EDT |  | PSTI | Pluristem reports progress of Phase I/II clinical trial of PLX cells
Pluristem Therapeutics reported on the progress of its ongoing double blind Phase I/II clinical trial to test the safety and efficacy of its PLacental Expanded, or PLX, cells in the treatment of muscle injury. This is the first time PLX cells have been used in patients following surgically induced muscle trauma. The primary endpoint of the study is safety with a secondary endpoint of gluteal muscle function at 6 months with the ability to perform biopsies of the involved muscle. PLX cells will be injected directly into the surgical incision after it has been sutured. Three groups of six patients will be enrolled in the study. The first group of six patients has been dosed without a significant adverse event related to either the placebo or the PLX cell product candidate. | |
|
News For PSTI From The Last 14 Days Check below for free stories on PSTI the last two weeks. |
|
|
| May 13, 2013 | | 06:23 EDT |  | PSTI | Pluristem Therapeutics' PLX cells may be effective in treating preeclampsia
 Subscribe for More Information | | | May 8, 2013 | | 07:12 EDT | | PSTI | Pluristem Therapeutics announces Phase 1 trial to study PLX-PAD cells
Pluristem announced a new Phase I trial to check safety and evaluate effectiveness of its PLX-PAD cells in chronic tendonitis often leading to rotator cuff disorders, common in tennis players and golfers, where there are roughly 200,000 rotator cuff surgeries done each year in the US alone. Major insurers put the overall cost of rotator cuff operations at $6,700 each, with a lucrative $1,700 in doctor fees, draining our health care system of over $1.3B. | | | May 7, 2013 | | 05:47 EDT | | PSTI | Pluristem Therapeutics develops PLX-RAD cells for use in Hematology
Subscribe for More Information | |
|
|
|
|
|
|
